S10:E1 – Oncology Morning Commute: Third-Line Treatment of CML

Hematology / Oncology @Point of Care Podcasts

English - May 15, 2022 17:00 - 17 minutes - 23.6 MB
Medicine Health & Fitness checkpointinhibitors cmece endometrialcancer immunotherapy Homepage Download Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: S9:E1 – Oncology Journal Club: Covid-19 and CLL Implications for Treatment Decision-Making

Next Episode: S10:E2 – Oncology Morning Commute: Targeting STAMP in CML

Third-line treatment of chronic myeloid leukemia and in particular BCR-ABL1 tyrosine kinase inhibitors are the latest therapeutics in the clinician’s toolbox. In this podcast, our faculty discuss these treatments and which patients can derive the most benefit from them.

Visit http://www.morningcommutepodcast.com/CML1 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit